CS MEDICA A/S, a MedTech innovator in cannabinoid-infused treatments, has entered a partnership with an undisclosed fast-growing, award-winning German OTC company. This company holds a strong position in the chronic pain segment in German pharmacies and is actively seeking innovative products to expand its own-labeled CBD portfolio. The collaboration will start with the MDR-compliant medical device; the Pain Patch, with the first 10.000 (10T) units ordered-more products are likely to be added later. The Pain Patch's launch is scheduled for Q3-2024. Detailed information will be published on launch day.

This partnership underscores CS MEDICA's strategic focus on Europe with Germany, a key market due to its size and maturity for CBD-infused products, mirroring the growing interest in the UK, Italy, and other EU markets. With this launch, CS MEDICA extends its commitment to providing natural, science-based, and effective health solutions. Additionally, the expedited process from initial contact to a paid invoice in just nine days is a testament to the company's market responsiveness and improved efficiency.

For further insights into CS MEDICA and the innovative Pain Patch, please visit https://www.cs-medica.com/ and https://www.cannasen.com/product/pain-patch (https://www.cannasen.dk/en/pain-patch)